ClinicalTrials.gg
CompletedNCT05119855Updated Feb 5, 2026Results posted

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

A Phase 3 interventional study of 9vHPV Vaccine and mRNA-1273 Vaccine in Papillomavirus Infections and Coronavirus Disease (COVID-19), sponsored by Merck Sharp & Dohme LLC. Completed at 38 sites in United States. Open to participants aged 9 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
9 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Enrollment
25th of 31
165 · median 700
Started
2022
with 4 others
Phase 3
16 of 31
2 open now
Registered
20th of 31
by date
Lead sponsor
15 of 31
Merck Sharp & Dohme LLC

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 25th largest by enrollment, is one of 5 that started in 2022, is one of 16 in phase 3, and was the 20th registered.

Papillomavirus Infections

577 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 9 Years to 11 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.

03

Conditions studied

  • Papillomavirus Infections
  • Coronavirus Disease (COVID-19)
04

Who can participate

Ages eligible
9 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has not yet had coitarche and does not plan on becoming sexually active during the vaccination period
  • Participant or participant's legally acceptable representative can read, understand, and complete the electronic vaccination report card (eVRC).

Exclusion criteria

Exclusion Criteria:

  • Known allergy to any vaccine component
  • History of severe allergic reaction that required medical intervention
  • Thrombocytopenia or any coagulation disorder
  • Has a history of myocarditis or pericarditis
  • Has a history of a clinical or microbiological diagnosis of COVID-19 ≤90 days prior to Day 1 visit or history of multisystem inflammatory syndrome in children (MIS-C) at any time prior to Day 1 visit
  • Females only: participant is pregnant
  • Currently , or been diagnosed with immunodeficiency
  • Had a splenectomy
  • Receiving or has received immunosuppressive therapies within the last year
  • Received any immunoglobulin product or blood-derived product within 3 months
  • Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Concomitant Group

    Participants will receive Dose 1 of 9-valent human papillomavirus \[Types 6, 11, 16, 18, 31, 33, 45, 52, 58\] (9vHPV) vaccine administered into the left arm as an intramuscular (IM) injection, AND Dose 1 of the messenger ribonucleic acid (mRNA)-1273 vaccine administered into the right arm as an IM injection on Day 1; participants will then receive Dose 2 of the mRNA-1273 vaccine administered into the right arm as an IM injection at Month 1 and Dose 2 of the 9vHPV vaccine administered into the left arm as an IM injection at Month 6.

    Biological: 9vHPV Vaccine · Biological: mRNA-1273 Vaccine

  • Experimental
    Non-concomitant Group

    Participants will receive Dose 1 of the mRNA-1273 vaccine administered into the right arm as an IM injection on Day 1 and Dose 2 of the mRNA-1273 vaccine administered into the right arm as an IM injection at Month 1. Participants will then receive Dose 1 of the 9vHPV vaccine administered into the left arm as an IM injection at Month 2 and Dose 2 of the 9vHPV vaccine administered into the left arm as an IM injection at Month 8.

    Biological: 9vHPV Vaccine · Biological: mRNA-1273 Vaccine

Interventions

  • Biological9vHPV Vaccine

    9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular (IM) injection

    Also known as: V503, GARDASIL®9, SILGARD®9

  • mRNA-1273 50 mcg dose administered as a 0.25-mL IM injection

    Also known as: SARS-CoV-2 Vaccine, Moderna COVID-19 Vaccine

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers of Anti-Human Papillomavirus Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (9vHPV)

    Antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) are reported for both arms for all randomized participants included in the per-protocol immunogenicity (PPI) population. The PPI population is HPV-type specific.

    Time frame: Up approximately 4 weeks post vaccination with 9vHPV Dose 2

  2. Geometric Mean Concentrations of SARS-CoV-2 Spike Protein-Specific Binding Antibodies

    The geometric mean concentration (GMC) of serum-derived antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein was determined using an electrochemiluminescence (ECL) assay. GMCs are reported for both arms for all randomized participants included in the mRNA-1273 per-protocol (mRNA-1273-PP) population.

    Time frame: Up approximately 4 weeks post vaccination with mRNA-1273 Dose 2

  3. Percentage of Participants With ≥1 Solicited Injection-site Adverse Event (AE)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited AEs are predefined local AEs (at the injection site) for which the participant was specifically questioned, and noted by the participant in their vaccine report card (VRC). Per protocol, the percentage of participants with ≥1 solicited injection site AE has been reported separately based on injection site for participants in the Concomitant Group (Day 1 mRNA-1273 Dose 1 right arm; Day 1 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Group (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting for Concomitant Group Day 1 Dose 1 separated by injection site is specific to this outcome only and does not apply to other safety outcomes.

    Time frame: Up to approximately Day 7 post vaccination with any study vaccine

  4. Percentage of Participants With ≥1 Solicited Systemic AE

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited AEs are predefined systemic events for which the participant is specifically questioned, and which are noted by the participant in their VRC. Per protocol the percentage of participants who experienced ≥1 solicited systemic (affecting the whole body) AE are reported here for participants in the Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.

    Time frame: Up to approximately Day 7 post vaccination with any study vaccine

  5. Percentage of Participants With ≥1 Serious Adverse Event (SAE)

    A serious adverse event (SAE) was defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention. Per protocol the percentage of participants who experienced ≥1 SAE are reported here for participants in the Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.

    Time frame: Up to approximately Day 28 post vaccination with any study vaccine

  6. Percentage of Participants With ≥1 Vaccine-Related SAE

    A SAE was defined as one that results in death, is life threatening, or requires hospitalization/prolongation of existing hospitalization, results in persistent/significant disability/incapacity, is a congenital anomaly/birth defect, or other important medical event that may require medical intervention. An SAE judged by the investigator to be related to the study vaccine is a vaccine-related SAE. Per protocol the percentage of participants who experienced ≥1 vaccine-related SAE are reported here for participants in Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.

    Time frame: Up to approximately 9 Months

Secondary outcomes

  1. Percentage of Participants Who Seroconvert to Each of the 9vHPV Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 Following Administration of a 2-Dose Regimen of 9vHPV Vaccine

    Serum-derived antibodies to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured with a competitive luminex immunoassay (cLIA). Seroconversion is defined as changing from cLIA anti-HPV seronegative serum antibodies for 9vHPV types at pre-vaccination to cLIA anti-HPV seropositive at 4 weeks post vaccination with 9vHPV Dose 2. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL) for HPV types were as follows: HPV Type 6: ≥34, HPV Type 11: ≥25; HPV Type 16: ≥32, HPV Type 18: ≥26, HPV Type 31: ≥15, HPV Type 33: ≥10, HPV Type 45: ≥10, HPV Type 52: ≥14, and HPV Type 58: ≥10. Percentage of participants who seroconverted are reported for both arms for all randomized participants included in the PPI population. The PPI population is HPV-type specific.

    Time frame: Up to approximately 4 weeks post vaccination with 9vHPV Dose 2

  2. Percentage of Participants Who Experience Seroresponse Following Administration of a 2-Dose Regimen of mRNA-1273 Vaccine

    Serum-derived antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein was determined using an electrochemiluminescence (ECL) assay. Seroresponse is defined as a ≥4-fold rise in SARS-CoV-2 spike protein-specific binding antibody concentration from baseline to 4 weeks post vaccination with mRNA-1273 Dose 2. Percentage of participants who experience seroresponse are reported for both arms for all randomized participants included in the mRNA-1273-PP population.

    Time frame: Up to approximately 4 weeks post vaccination with mRNA-1273 Dose 2

07

Results

Posted Jul 17, 2025

Participant flow

Participant flow — Overall Study
MilestoneConcomitant GroupNon-concomitant Group
Started8283
Vaccinated: mrna-1273 dose 18181
Vaccinated: 9vhpv dose 18172
Vaccinated: mrna-1273 dose 27878
Vaccinated: 9vhpv dose 26766
Concomitant group dose 1 day 1: 9vhpv810
Concomitant group dose 1 day 1: mrna-1273810
Concomitant group dose 2 month 1: mrna-1273780
Concomitant group dose 2 month 6: 9vhpv670
Non-concomitant group dose 1 day 1: mrna-1273081
Non-concomitant group dose 2 month 1: mrna-1273078
Non-concomitant group dose 1 month 2: 9vhpv072
Non-concomitant group dose 2 month 8: 9vhpv066
Completed6664
Not completed1619
Withdrew: Randomized by mistake without study treatment01
Withdrew: Withdrawal by parent/guardian1010
Withdrew: Lost to follow-up68

Outcome measures

PrimaryGeometric Mean Titers of Anti-Human Papillomavirus Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (9vHPV)

Antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) are reported for both arms for all randomized participants included in the per-protocol immunogenicity (PPI) population. The PPI population is HPV-type specific.

Time frame:
Up approximately 4 weeks post vaccination with 9vHPV Dose 2
Reported as:
Geometric mean · mMU/mL
Geometric Mean Titers of Anti-Human Papillomavirus Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (9vHPV)
mMU/mLConcomitant GroupNon-concomitant Group
Anti-HPV 62198.5 (1806.9 to 2674.8)1806.8 (1481.8 to 2202.9)
Anti-HPV 111517.6 (1247.5 to 1846.2)1138.2 (941.4 to 1376.2)
Anti-HPV 169595.8 (7822.5 to 11771.0)7042.3 (5728.2 to 8657.7)
Anti-HPV 182139.2 (1721.3 to 2658.6)1713.2 (1372.1 to 2139.1)
Anti-HPV 311695.6 (1383.9 to 2077.3)1404.7 (1149.0 to 1717.2)
Anti-HPV 331172.3 (950.8 to 1445.5)889.9 (720.2 to 1099.6)
Anti-HPV 45518.0 (413.0 to 649.6)370.8 (293.6 to 468.4)
Anti-HPV 52733.6 (614.4 to 875.9)504.7 (421.9 to 603.7)
Anti-HPV 581095.2 (900.5 to 1332.1)912.6 (750.3 to 1110.0)
Statistical analysis
  • Concomitant Group vs Non-concomitant Group · Geometric mean titer (gmt) ratio: 1.22 · 95% CI 0.92 to 1.61GMT Ratio is between Concomitant Group/Non-concomitant Group.
  • Concomitant Group vs Non-concomitant Group · Geometric mean titer (gmt) ratio: 1.33 · 95% CI 1.01 to 1.75GMT Ratio is between Concomitant Group/Non-concomitant Group.
  • Concomitant Group vs Non-concomitant Group · Geometric mean titer (gmt) ratio: 1.36 · 95% CI 1.02 to 1.82GMT Ratio is between Concomitant Group/Non-concomitant Group.
  • Concomitant Group vs Non-concomitant Group · Geometric mean titer (gmt) ratio: 1.25 · 95% CI 0.92 to 1.70GMT Ratio is between Concomitant Group/Non-concomitant Group.
  • Concomitant Group vs Non-concomitant Group · Geometric mean titer (gmt) ratio: 1.21 · 95% CI 0.91 to 1.61GMT Ratio is between Concomitant Group/Non-concomitant Group.
  • Concomitant Group vs Non-concomitant Group · Geometric mean titer (gmt) ratio: 1.32 · 95% CI 0.98 to 1.77GMT Ratio is between Concomitant Group/Non-concomitant Group.
  • Concomitant Group vs Non-concomitant Group · Geometric mean titer (gmt) ratio: 1.40 · 95% CI 1.01 to 1.93GMT Ratio is between Concomitant Group/Non-concomitant Group.
  • Concomitant Group vs Non-concomitant Group · Geometric mean titer (gmt) ratio: 1.45 · 95% CI 1.13 to 1.87GMT Ratio is between Concomitant Group/Non-concomitant Group.
  • Concomitant Group vs Non-concomitant Group · Geometric mean titer (gmt) ratio: 1.20 · 95% CI 0.91 to 1.58GMT Ratio is between Concomitant Group/Non-concomitant Group.
PrimaryGeometric Mean Concentrations of SARS-CoV-2 Spike Protein-Specific Binding Antibodies

The geometric mean concentration (GMC) of serum-derived antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein was determined using an electrochemiluminescence (ECL) assay. GMCs are reported for both arms for all randomized participants included in the mRNA-1273 per-protocol (mRNA-1273-PP) population.

Time frame:
Up approximately 4 weeks post vaccination with mRNA-1273 Dose 2
Reported as:
Geometric mean · μg/mL
Geometric Mean Concentrations of SARS-CoV-2 Spike Protein-Specific Binding Antibodies
μg/mLConcomitant GroupNon-concomitant Group
Geometric Mean Concentrations of SARS-CoV-2 Spike Protein-Specific Binding Antibodies763084.3 (673224.4 to 864938.4)650527.9 (576365.9 to 734232.5)
Statistical analysis
  • Concomitant Group vs Non-concomitant Group · Geometric mean concentration (gmc) ratio: 1.17 · 95% CI 0.99 to 1.40GMC Ratio is between Concomitant Group/Non-concomitant Group.
PrimaryPercentage of Participants With ≥1 Solicited Injection-site Adverse Event (AE)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited AEs are predefined local AEs (at the injection site) for which the participant was specifically questioned, and noted by the participant in their vaccine report card (VRC). Per protocol, the percentage of participants with ≥1 solicited injection site AE has been reported separately based on injection site for participants in the Concomitant Group (Day 1 mRNA-1273 Dose 1 right arm; Day 1 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Group (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting for Concomitant Group Day 1 Dose 1 separated by injection site is specific to this outcome only and does not apply to other safety outcomes.

Time frame:
Up to approximately Day 7 post vaccination with any study vaccine
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥1 Solicited Injection-site Adverse Event (AE)
Percentage of ParticipantsConcomitant GroupNon-concomitant Group
Concomitant Group: Day 1 -mRNA-1273 Dose 1 (right arm)49.4—
Concomitant Group: Day 1 - 9vHPV Dose 1 (left arm)39.5—
Concomitant Group: Month 1 - mRNA-1273 Dose 2 (right arm)35.9—
Concomitant Group: Month 6 - 9vHPV Dose 2 (left arm)26.9—
Non-concomitant Group: Day 1 - mRNA-1273 Dose 1 (right arm)—55.6
Non-concomitant Group: Month 1 -mRNA-1273 Dose 2 (right arm)—44.9
Non-Concomitant Group: Month 2 - 9vHPV Dose 1 (left arm)—29.2
Non-concomitant Group: Month 8 - 9vHPV Dose 2 (left arm)—43.9
PrimaryPercentage of Participants With ≥1 Solicited Systemic AE

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited AEs are predefined systemic events for which the participant is specifically questioned, and which are noted by the participant in their VRC. Per protocol the percentage of participants who experienced ≥1 solicited systemic (affecting the whole body) AE are reported here for participants in the Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.

Time frame:
Up to approximately Day 7 post vaccination with any study vaccine
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥1 Solicited Systemic AE
Percentage of ParticipantsConcomitant GroupNon-concomitant Group
Concomitant Group: Day 1 - 9vHPV Dose 1 + mRNA-1273 Dose 133.3—
Concomitant Group: Month 1 - mRNA-1273 Dose 233.3—
Concomitant Group: Month 6 - 9vHPV Dose 217.9—
Non-concomitant Group: Day 1 - mRNA-1273 Dose 1—37.0
Non-concomitant Group: Month 1 - mRNA-1273 Dose 2—33.3
Non-concomitant Group: Month 2 - 9vHPV Dose 1—16.7
Non-concomitant Group: Month 8 - 9vHPV Dose 2—10.6
PrimaryPercentage of Participants With ≥1 Serious Adverse Event (SAE)

A serious adverse event (SAE) was defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention. Per protocol the percentage of participants who experienced ≥1 SAE are reported here for participants in the Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.

Time frame:
Up to approximately Day 28 post vaccination with any study vaccine
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥1 Serious Adverse Event (SAE)
Percentage of ParticipantsConcomitant GroupNon-concomitant Group
Concomitant Group: Day 1 - 9vHPV Dose 1 + mRNA-1273 Dose 10.0—
Concomitant Group: Month 1 - mRNA-1273 Dose 20.0—
Concomitant Group: Month 6 - 9vHPV Dose 20.0—
Non-concomitant Group: Day 1 - mRNA-1273 Dose 1—0.0
Non-concomitant Group: Month 1 - mRNA-1273 Dose 2—0.0
Non-concomitant Group: Month 2 - 9vHPV Dose 1—0.0
Non-concomitant Group: Month 8 - 9vHPV Dose 2—0.0
PrimaryPercentage of Participants With ≥1 Vaccine-Related SAE

A SAE was defined as one that results in death, is life threatening, or requires hospitalization/prolongation of existing hospitalization, results in persistent/significant disability/incapacity, is a congenital anomaly/birth defect, or other important medical event that may require medical intervention. An SAE judged by the investigator to be related to the study vaccine is a vaccine-related SAE. Per protocol the percentage of participants who experienced ≥1 vaccine-related SAE are reported here for participants in Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.

Time frame:
Up to approximately 9 Months
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥1 Vaccine-Related SAE
Percentage of ParticipantsConcomitant GroupNon-concomitant Group
Concomitant Group: Day 1 - 9vHPV Dose 1 + mRNA-1273 Dose 10.0—
Concomitant Group: Month 1 - mRNA-1273 Dose 20.0—
Concomitant Group: Month 6 - 9vHPV Dose 20.0—
Non-concomitant Group: Day 1 - mRNA-1273 Dose 1—0.0
Non-concomitant Group: Month 1 - mRNA-1273 Dose 2—0.0
Non-concomitant Group: Month 2 - 9vHPV Dose 1—0.0
Non-concomitant Group: Month 8 - 9vHPV Dose 2—0.0
SecondaryPercentage of Participants Who Seroconvert to Each of the 9vHPV Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 Following Administration of a 2-Dose Regimen of 9vHPV Vaccine

Serum-derived antibodies to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured with a competitive luminex immunoassay (cLIA). Seroconversion is defined as changing from cLIA anti-HPV seronegative serum antibodies for 9vHPV types at pre-vaccination to cLIA anti-HPV seropositive at 4 weeks post vaccination with 9vHPV Dose 2. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL) for HPV types were as follows: HPV Type 6: ≥34, HPV Type 11: ≥25; HPV Type 16: ≥32, HPV Type 18: ≥26, HPV Type 31: ≥15, HPV Type 33: ≥10, HPV Type 45: ≥10, HPV Type 52: ≥14, and HPV Type 58: ≥10. Percentage of participants who seroconverted are reported for both arms for all randomized participants included in the PPI population. The PPI population is HPV-type specific.

Time frame:
Up to approximately 4 weeks post vaccination with 9vHPV Dose 2
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Seroconvert to Each of the 9vHPV Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 Following Administration of a 2-Dose Regimen of 9vHPV Vaccine
Percentage of ParticipantsConcomitant GroupNon-concomitant Group
Anti-HPV 6 cLIA ≥34 mMU/ mL100.0 (92.5 to 100.0)100.0 (92.3 to 100)
Anti-HPV 11 cLIA ≥25 mMU/ mL100.0 (92.3 to 100.0)100.0 (92.7 to 100.0)
Anti-HPV 16 cLIA ≥32 mMU/ mL100.0 (92.5 to 100.0)100.0 (92.3 to 100.0)
Anti-HPV 18 cLIA ≥26 mMU/ mL100.0 (92.6 to 100.0)100.0 (92.3 to 100.0)
Anti-HPV 31 cLIA ≥15 mMU/ mL100.0 (92.3 to 100.0)100.0 (92.5 to 100.0)
Anti-HPV 33 cLIA ≥10 mMU/ mL100.0 (92.6 to 100.0)100.0 (92.5 to 100.0)
Anti-HPV 45 cLIA ≥10 mMU/ mL100.0 (92.9 to 100.0)100.0 (92.5 to 100.0)
Anti-HPV 52 cLIA ≥14 mMU/ mL100.0 (92.7 to 100.0)100.0 (92.6 to 100.0)
Anti-HPV 58 cLIA ≥10 mMU/ mL100.0 (92.6 to 100.0)100.0 (92.6 to 100.0)
SecondaryPercentage of Participants Who Experience Seroresponse Following Administration of a 2-Dose Regimen of mRNA-1273 Vaccine

Serum-derived antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein was determined using an electrochemiluminescence (ECL) assay. Seroresponse is defined as a ≥4-fold rise in SARS-CoV-2 spike protein-specific binding antibody concentration from baseline to 4 weeks post vaccination with mRNA-1273 Dose 2. Percentage of participants who experience seroresponse are reported for both arms for all randomized participants included in the mRNA-1273-PP population.

Time frame:
Up to approximately 4 weeks post vaccination with mRNA-1273 Dose 2
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Seroresponse Following Administration of a 2-Dose Regimen of mRNA-1273 Vaccine
Percentage of ParticipantsConcomitant GroupNon-concomitant Group
Percentage of Participants Who Experience Seroresponse Following Administration of a 2-Dose Regimen of mRNA-1273 Vaccine96.4 (87.7 to 99.6)95.0 (86.1 to 99.0)

Adverse events

Collected over Up to approximately 9 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Concomitant Group0/82 (0%)0/81 (0%)55/81 (67.9%)
Non-concomitant Group0/83 (0%)0/81 (0%)59/81 (72.8%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventConcomitant GroupNon-concomitant Group
Injection site painGeneral disorders46/8152/81
HeadacheNervous system disorders26/8130/81
FatigueGeneral disorders23/8123/81
LymphadenopathyBlood and lymphatic system disorders6/8120/81
Injection site swellingGeneral disorders14/8118/81
MyalgiaMusculoskeletal and connective tissue disorders9/8116/81
ChillsGeneral disorders13/8111/81
Injection site erythemaGeneral disorders6/8112/81
PyrexiaGeneral disorders11/8110/81
ArthralgiaMusculoskeletal and connective tissue disorders7/8110/81

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Concomitant GroupNon-concomitant GroupTotal
Mean9.9 ± 0.99.9 ± 0.89.9 ± 0.8
Sex: Female, Male
Sex: Female, Male(Participants)Concomitant GroupNon-concomitant GroupTotal
Female434588
Male393877
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Concomitant GroupNon-concomitant GroupTotal
Hispanic or Latino504696
Not Hispanic or Latino323769
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Concomitant GroupNon-concomitant GroupTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American283159
White5348101
More than one race022
Unknown or Not Reported022
08

Study locations

38 sites
  • Cognitive Clinical Trials, LLC ( Site 0054)
    Phoenix, Arizona 85044, United States
  • Eclipse Clinical Research ( Site 0095)
    Tucson, Arizona 85745, United States
  • Children's Clinic of Jonesboro, PA ( Site 0044)
    Jonesboro, Arkansas 72401, United States
  • Preferred Research Partners Inc. ( Site 0092)
    Little Rock, Arkansas 72211, United States
  • Coast Clinical Research, LLC ( Site 0027)
    Bellflower, California 90706, United States
  • Ark Clinical Research ( Site 0098)
    Long Beach, California 90815, United States
  • Valley Clinical Trials Inc. ( Site 0004)
    Northridge, California 91325, United States
  • Medical Center for Clinical Research ( Site 0051)
    San Diego, California 92120, United States
  • Ark Clinical Research ( Site 0108)
    Tustin, California 92780, United States
  • Emerson Clinical Research Institute ( Site 0021)
    Washington D.C., District of Columbia 20011, United States
  • Accel Research Sites-DeLand Clinical Research Unit ( Site 0066)
    DeLand, Florida 32720, United States
  • Advanced Research for Health Improvement, LLC ( Site 0012)
    Immokalee, Florida 34142, United States
  • Acevedo Clinical Research Associates ( Site 0001)
    Miami, Florida 33142, United States
  • Alpha Science Research ( Site 0067)
    Miami, Florida 33186, United States
  • Advanced Research For Health Improvement LLC ( Site 0075)
    Naples, Florida 34102, United States
  • Comprehensive Clinical Research ( Site 0038)
    West Palm Beach, Florida 33409, United States
  • Atlanta Center for Medical Research ( Site 0055)
    Atlanta, Georgia 30331, United States
  • Mount Vernon Clinical Research ( Site 0053)
    Sandy Springs, Georgia 30328, United States
  • Clinical Research Prime ( Site 0088)
    Idaho Falls, Idaho 83404, United States
  • CBH Health ( Site 0019)
    Gaithersburg, Maryland 20877, United States
  • SKY Integrative Medical Center/SKYCRNG ( Site 0084)
    Ridgeland, Mississippi 39157, United States
  • Midwest Children's Health Research Institute ( Site 0003)
    Lincoln, Nebraska 68505, United States
  • Certified Research Associates ( Site 0090)
    Cortland, New York 13045, United States
  • Corning Center for Clinical Research ( Site 0091)
    Horseheads, New York 14845, United States
  • Carolina Institute for Clinical Research, LLC ( Site 0042)
    Fayetteville, North Carolina 28303, United States
  • M3 Wake Research, Inc. ( Site 0014)
    Raleigh, North Carolina 27612, United States
  • Dayton Clinical Research ( Site 0028)
    Dayton, Ohio 45409, United States
  • Thomas Jefferson University - Family and Community Medicine ( Site 0006)
    Philadelphia, Pennsylvania 19107, United States
  • WR-ClinSearch ( Site 0049)
    Chattanooga, Tennessee 37421, United States
  • DermResearch, Inc. ( Site 0056)
    Austin, Texas 78759, United States
  • South Texas Clinical Research ( Site 0024)
    Corpus Christi, Texas 78404, United States
  • South Texas Pediatric Research Group ( Site 0094)
    Del Rio, Texas 78840, United States
  • West Houston Clinical Research Services ( Site 0078)
    Houston, Texas 77055, United States
  • Next Level Urgent Care, LLC ( Site 0099)
    Houston, Texas 77057, United States
  • Milton Haber, M.D. ( Site 0069)
    Laredo, Texas 78041, United States
  • University of Texas Medical Branch ( Site 0026)
    League City, Texas 77573, United States
  • University of Utah ( Site 0076)
    Salt Lake City, Utah 84132, United States
  • Velocity Clinical Research, Salt Lake City ( Site 0025)
    West Jordan, Utah 84088, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Dec 2023, 20 months.

Results were first posted in Jul 2025, 1 year 7 months after primary completion. A results delay was requested in Nov 2024.

Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 20 months is below that.

Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2021
First posted
Nov 15, 2021
StartActual
Mar 28, 2022
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Results delay requested
Nov 4, 2024
Results first posted
Jul 17, 2025
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05119855
Responsible party
Sponsor
First posted
Nov 15, 2021
Start date
Mar 28, 2022
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Results posted
Jul 17, 2025
Last update
Feb 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Human Papillomavirus Recombinant Vaccine nonavalent · 2019-nCoV Vaccine mRNA-1273

Start the discussion